MANNKIND - 2013 endlich zum Überflieger?

Interessanter Artikel.
Dennoch erscheint mir die Aktivität bei Mannkind eher als verzweifelte Suche nach einer neuen Story und somit neuen Geldquellen.
Seit Jahren hat der Laden nicht wirklich etwas geliefert, was berechtigt hoffen liese.

www.fool.com/investing/2020/06/17/...soaring-again-today.aspx

Zahlen für Q1/20

• Umsatz 16 Mio. $
  
• Verlust 9 Mio. $
  
• Cash 39 Mio. $
  
• negatives Eigenkapital 198 Mio. $
  
• MK 413 Mio. $
  

investors.mannkindcorp.com/news-releases/...quarter-financial

Zahlen für Q2/20

• Umsatz 15 Mio. $
  
• Verlust 10 Mio. $
  
• Cash 63 Mio. $
  
• negatives Eigenkapital 180 Mio. $
  
• MK 347 Mio. $
  

investors.mannkindcorp.com/news-releases/...quarter-financial

alles sitzt in Wartestellung, hab mal eine kleine anfangs Posi. mir ins Depot gelegt.
ich vertraue meiner Glaskugel.
s2

So, as we get into the agenda, we’re going to go through our Q3 highlights, the financial review of Steve and Q4 expectations and then a Q&A.

I just want to remind people about our mission, which is really to give people control of their health and the freedom to live life, and we call it, life more humann.

Our technology really helps provide quick relief of patients’ symptoms, such as high sugar, pulmonary hypertension, and migraine, almost at the onset of action and being able to correct that with the quick inhalation using our platform. We’re very excited to continue to expand our technology into other assets as we continue to move R&D forward.

I’d also like to announce recent new addition to our team, Dr. Kevin Kaiserman, who now will be our Head of Medical Affairs and Safety. And new week, we expect to also announce a new head of regulatory. Kevin has 25 years of pediatric endocrinology experience, which we felt was very valuable, given our direction to move further into pediatrics in 2021. He is well-respected as a thought leader. He had private practice here in California and was trained at Children’s Hospital of LA. He’ll be leading our medical affairs, expanded field medical team, our safety and our pediatrics program.

Let me talk about a few of the Q3 highlights. Afrezza third quarter net revenue of $7.3 million with 27% ahead of Q3 of 2019. In the U.S., our total prescription grew 8% and sequentially 3% in quarter two. The market was down 3% over -- year-over-year for rapid-acting analogs, and 2% quarter-over-quarter respectively. So, we’re outpacing the market shrinkage and we’re continuing to grow year-over-year, despite the headwinds that COVID-19 presents.

Access is continuing to open up for our field reps reaching customers in the field. Obviously, certain areas of the country are more difficult than others, but our team has done a very decent job given the difficult circumstances they face.

Our U.S. September year-to-date net revenue is $22.1 million or 31% versus 2019 and our trend is starting to pick up nicely in Q4, as we hope to see scripts [ph] up this Friday.

Our United Therapeutics collaboration with TreT remains on track to complete the critical NDA components here in Q4. And we recently received a $1.2 million purchase order for clinical supplies as we get to Q4 in 2021 and beyond.

Our cash at the end of the quarter was $52.7 million and we used $13.5 million in operating activities. We also reduced our debt by $2.6 million in October by prepaying our December promissory note and at schedule.


Like this article
Single page viewpage 1 / 9 | Next »
Recommended for you:
Warren Ludford
Tesla Is Being Overtaken (NASDAQ:TSLA)
Warren Ludford
Librarian Capital
Altria: With Strong Q3 Results, This Stock Could Double By 2023 Year-End (NYSE:MO)
Librarian Capital
SA Transcripts
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call Transcript
SA Transcripts
SA Transcripts
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2020 Results - Earnings Call Transcript
SA Transcripts
Comments 0 Sort by
          §
Add Your Comment
Be the first to comment
Your feedback matters to us!
Error in this transcript? Let us know.
Contact us to add your company to our coverage or use transcripts in your business.
Learn more about Seeking Alpha transcripts here.



SEARCH TRANSCRIPT
This transcript
e.g. "this quarter"
All transcripts
e.g. "this quarter"
COMPARE TO:
All MNKD Transcripts
Other Companies in this sector


RSS Feeds|Advertise with Us|Sitemap|About Us|Feedback|Careers|Contact Us
Terms of Use|Privacy|Market Data Sources|© 2020 Seeking Alpha

Zahlen für Q3/20

• Umsatz 15 Mio. $
  
  • davon 7 Mio. $ Produktumsätze
    
  • und 8 Mio. $ Kollaboration /Services
    
• Verlust 11 Mio. $
  
• Cash 53 Mio. $
  
• negatives Eigenkapital 186 Mio. $
  
• MK 474 Mio. $
  

Die hohe Bewertung wird mir wohl weiterhin ein Rätsel bleiben. Hohe Schulden, Verluste, Verwässerung und ein langsames Umsatzwachstum.

investors.mannkindcorp.com/news-releases/...quarter-financial

Squeeze?

Erstaunlich, so ganz ohne News.

Gewinnmitnahmen gestern sehr wacker gehalten.

Bin gespannt was da noch möglich ist.

wieder was gehen....

WARUM (?) bekommt Ihr das nicht langsam mal in den Griff mit diesen Schmuddelseiten ?
Wollt Ihr nicht o. könnt Ihr nicht ???
Das nimmt langsam ein Ausmaß an was nicht mehr akzeptabel ist !!!
Ausserdem schadet es der Reputation von ARIVA auf das Äußerste, aber dies werden Sie ja hoffentlich selbst wissen …
MfG K.H.

schlecht gelaufen, hier wird es bald zwei oder sogar dreistellig.
s2

...man kann nicht immer alles haben ;-)

“No immediate-acting treatments for these conditions are currently available, so an inhaled CBD, like RLS103, with an ultra-rapid onset, has the potential to address this need in both disorders,” said Andrea Leone-Bay, PhD, Founder and Chief Scientific Officer of Receptor Life Sciences. RLS103 is a drug-device combination product based on the Technosphere® dry powder inhalation system licensed from MannKind Corporation.

RDD 2021 is the premier international conference for scientists and drug developers focused on pulmonary and nasal drug delivery. This year, RDD is a virtual conference and Receptor’s poster presentations can be viewed online by conference participants between April 27 and June 20.

   “Using Inhalation to Bypass First-Pass Metabolism as a Means of Improving Cannabidiol Bioavailability,” Kelly S. Kraft, Orrin Devinsky, Lorraine Rusch, Melanie Fein, and Andrea Leone-Bay; and
   “An Indirect Pharmacokinetic Comparison of Cannabidiol Formulations: Dry Power Inhaled (DPI) vs Vaporization,” Andrea Leone-Bay, Orrin Devinsky, Lorraine Rusch, Melanie Fein, and Kelly S. Kraft.

Panic disorder affects about 5.4 million adults in the United States, according to the National Institute of Mental Health. Social Anxiety Disorder affects about 15 million adults in the U.S. and is the second-most commonly diagnosed anxiety disorder (adaa.org/understanding-anxiety/social-anxiety-disorder).

About Receptor Life Sciences

Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience. For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval see www.receptorlife.com.  

FDA verlängert die Frist um den Arzneimittelantrag (NDA) für Tyvaso DPI zu prüfen

• von Februar auf Mai 2022
  

seekingalpha.com/news/...xtends-deadline-to-review-tyvaso-dpi